While using “fresh” final products (not designed for long-term storage) in cell therapy manufacturing is perfectly acceptable for proof of concept of the cell therapy, as development into late-stage and then commercial production becomes the goal, different constraints arise. This is where cryopreservation of final product becomes an option and, in some cases, even a necessity.
In this nine-page whitepaper you will learn: